A Phase 1 interventional study of varegacestat in Healthy Volunteer and Hepatic Impairment (HI), sponsored by Immunome, Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years to 84 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-10.
Sponsored by Immunome, Inc. · Phase 1, Interventional, and Other
This clinical trial is designed to determine the pharmacokinetics, safety and tolerability of varegacestat in people with impaired liver function compared to people with normal liver function.
This is an open-label, single-dose, parallel study to evaluate the effects of varying degrees of impaired hepatic function on the PK, safety, and tolerability of varegacestat in adult participants.
The study will be conducted sequentially. The study will enroll participants with mild (Group 2) and moderate (Group 3) hepatic impairment (HI) and healthy participants with normal hepatic function (Group 1) at a 1:1 ratio. Matched healthy participants may match to more than one participant in the HI groups. Subsequently, if appropriate, the study will enroll participants with severe (Group 4) HI and healthy participants with normal hepatic function (Group 1), as needed, to provide 1:1 matches for Group 4. The decision to conduct Group 4 enrollment will be contingent upon the assessment of the feasibility, PK, and safety data from Groups 1-3.
Inclusion Criteria (Healthy Participants):
Inclusion Criteria (Hepatic Impairment):
Mild: ≥5 and ≤6 [Category A]; or
Moderate: ≥7 and ≤9 [Category B]; or
Severe: ≥10 and ≤15 [Category C].
- Medically healthy, apart from HI, with no clinically significant medical history, physical examination, clinical laboratory profiles, vital signs, and ECGs as deemed by the PI or designee
Exclusion Criteria (Healthy Volunteers):
Exclusion Criteria (Hepatic Impairment):
Participants must not be enrolled in the study, if they meet any of the following criteria:
Single oral dose of varegacestat administered on study day 1
Drug: varegacestat
experimental intervention
PK of varegacestat and metabolite from a single oral dose of varegacestat in hepatic impaired adult participants to matched healthy adult participants.
AUC0-t varegacestat and metabolite
Time frame: Up to 4 weeks
PK of varegacestat and metabolite from a single oral dose of varegacestat in hepatic impaired adult participants to matched healthy adult participants.
AUC0-inf for varegacestat and metabolite
Time frame: Up to 4 weeks
PK of varegacestat and metabolite from a single oral dose of varegacestat in hepatic impaired adult participants to matched healthy adult participants.
Cmax for varegacestat and metabolite
Time frame: Up to 4 weeks
Assess the safety and tolerability of a single oral dose of varegacestat in hepatic impaired adult participants and in matched healthy adult participants.
Number of subjects who experience treatment emergent adverse events (TEAEs)
Time frame: Up to 4 weeks
Assess the safety and tolerability of a single oral dose of varegacestat in hepatic impaired adult participants and in matched healthy adult participants.
Number of subjects who experience abnormalities in vital signs and in clinical laboratory tests such as serum chemistry and hematology
Time frame: Up to 4 weeks
Assess the safety and tolerability of a single oral dose of varegacestat in hepatic impaired adult participants and in matched healthy adult participants.
Number of subjects who experience 12-lead ECG abnormalities
Time frame: Up to 4 weeks
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Immunome, Inc.